Commonhold A venture studio by Peterson & Gill LLC
London · Nairobi
Our first company, AgentBI, is now rolling out in Kenya.
View AgentBI
A VENTURE STUDIO IN THE PUBLIC SECTOR

Building companies from
grant-funded R&D

We invent, build and co-found companies. We turn grant-funded public-sector programmes into software and service companies.
Grants de-risk initial testing and investment funds growth.

Many governments face the same problems.
They don’t each need their own project. One company can serve them all.

Read our founding thesis
OUR FIRST COMPANY

AgentBI

Live Demo

AgentBI surfaces task completion, supervision patterns, incentive uptake and retention signals as practical insight for programme managers, governments and funders. It is the business-intelligence layer for public-sector field workforces.

STATUS
Live build underway
ORIGIN
Field research, Kenya
GEOGRAPHY
Kenya Multi-country
SEED SASA
Crop Sales Agent · Kisumu
SCREENING
214Applied
96Skills-checked
8Surfaced to you
TOP MATCHES
94
Kisumu · 3 seasons
91
Kisumu · 4 seasons
88
Siaya · 2 seasons
THE FUNDS

Fund I

FRONTLINE ENABLEMENT
In deployment · Kenya and sub-Saharan Africa

Climate-resilient seeds and other inputs often fail to reach the farms they were developed for. Grants pay for field testing to show that a better delivery model works. A company then turns that proven approach into a product for the agribusinesses, lenders and programmes that already bear the cost of poor distribution. AgentBI is the first company from this fund. Commonhold is now looking for a second company focused solely on agriculture.

Fund II

HEALTH DELIVERY
In formation · Asia and sub-Saharan Africa

Essential medicines and health services reach remote communities through delivery systems that no one is responsible for maintaining. Across Southeast Asia and sub-Saharan Africa, donors commission supply chains, health workforces and payment systems for a single programme and country. These systems are built around grant requirements, without a paying customer or a sustainable business model. When the grant ends, they shut down, and the next programme builds them again.

Fund II creates companies that own and operate this infrastructure. They sell to the ministries, distributors and insurers that need medicines to arrive. That revenue keeps the system running after the original grant ends.

THE MODEL

Grants fund evidence.
Investors fund growth.

Tomorrow’s most impactful companies are already hiding inside public R&D. Commonhold is the engine that finds them. Because philanthropic grants have already absorbed the cost of years of learning, testing, and data collection, the core risk is mitigated. The question is no longer whether an idea works, but whether the market will sustainably pay for it.

Every year, governments, foundations, and NGOs spend millions piloting better delivery models in agriculture, health, education, and finance. While most of these initiatives remain temporary projects, a select few possess long-term commercial viability. Commonhold identifies these outliers and builds them into independent, venture-backed companies, each equipped with a dedicated team and shared institutional foundations.

Each of our funds targets a single public-service theme. Our evaluation engine analyses the existing grant-funded programmes in that theme and ruthlessly screens them against three core criteria:

ECONOMIC SUSTAINABILITY

Will a government or large institution pay for this over the long term?

SCALABILITY

Can the solution work beyond its first grant and country?

MARKET DEMAND

Does this exact problem exist at scale elsewhere?

We stress-test the strongest candidates alongside dedicated co-founders. Ultimately, we spin out one or two high-conviction companies per fund, retaining a hands-on role as an active institutional co-founder in every venture.

CAPITAL BY STAGE
1
STAGE 1 · FIELD EVIDENCE
Philanthropic capital
Grants de-risk the initial research and field testing. We validate the problem, market demand, and delivery model before a single dollar of equity is put at risk.
2
STAGE 2 · PRODUCT
Studio capital + grants
We incorporate the company and develop a commercially viable product tailored for international buyers. Commonhold takes approximately 60% equity at formation, strategically reserving capital for follow-on rounds.
3
STAGE 3 · COMMERCIAL SCALE
Recurring revenue + private capital
External investors enter once recurring revenue is established. Investors have the option to commit at formation, with capital drawn down only after successful grant-funded milestones are met. Our objective is to retain majority ownership through Series A.
THE TEAM

Operators from inside
the systems we build for

We have worked inside the systems these companies sell to, including UN agencies, national governments and global health programmes. We know where to look inside a programme, and what it takes to make it a business.

CO-FOUNDER
Nathanial (Nate) Peterson, PhD
Behavioural scientist and venture builder in farming markets and frontline services. He founded Burgeon Strategy, which helps social enterprises move from philanthropy to private investment, and was Regional Behavioural Specialist at the UN FAO. PhD in Behavioral Decision Research, Carnegie Mellon. When a severe drought in Kenya reached his own sheep farm, he turned to how climate-resilient seed reaches farmers.
CO-FOUNDER
Nishita Gill
Builds digital products for public systems at national scale. With the Government of India she redesigned the Aadhaar app, the national identity system now reachable by 1.35 billion people. She led digital product work for HIV, TB and hepatitis at the Clinton Health Access Initiative, founded the design studio Treemouse (30+ projects for clients including Meta, BCG and Omidyar Network) and was founding Head of Design at Fi.Money, India’s first major neobank. At Biome Ventures she built the venture pipeline that sparked the idea for Commonhold.
ADVISORS
Aman Siwach
Global health leader in market shaping. In six years at the Clinton Health Access Initiative (CHAI) he landed some of its biggest deals in infectious disease and nutrition, including the lenacapavir agreement for HIV prevention, hydroxyurea for sickle cell disease, ultraportable X-ray for TB and L-AmB for advanced HIV. In a single year, that work unlocked about $1.5 billion in savings.
Michael Campbell
Senior Director of Pharmacy Strategy at Mass General Brigham. At CHAI he grew the tuberculosis programme from two countries to more than 20 and negotiated price cuts of over 50% on TB medicines and diagnostics.
Chaning Jang
Chief Strategy Officer at Irrational Labs. He founded the Busara Center for Behavioral Economics in Nairobi and, as CEO, grew it to more than 140 staff on five continents.
DESIGN & BRANDING PARTNERS
HOW IT FITS TOGETHER
THE COMPANY
Peterson & Gill LLC
The legal entity and founding partnership.
THE STUDIO
Commonhold
The venture studio operated by the LLC. It finds, tests and co-founds the companies.
THE FUNDS
Thematic funds
Each tests prototype companies in one public-service theme and backs the most investable.
THE COMPANIES
AgentBI
Independent companies, each with its own team and accounts. The studio stays a co-founder.